New hope for tough breast cancer: Immune-Boosting drug tested before surgery
NCT ID NCT07256964
Summary
This study is testing whether adding an immunotherapy drug (toripalimab) to different chemotherapy combinations works better to shrink triple-negative breast cancer tumors before surgery. Researchers want to see which treatment plan is more effective and safer for patients. The goal is to find the best approach to control the cancer and improve long-term outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.